MAPK1

Across TCGA pan-cancer cohorts, MAPK1 mass-spec protein is linked to patient survival in 3 of 34 cancer types, making it a survival-associated MAPK1 data layer compared with 29 for mass-spec protein and 6 for mutation status.

The strongest signal is observed in pancreatic ductal adenocarcinoma (PDAC), where higher MAPK1 mass-spec protein is associated with better overall survival. In most high-consensus cancer types, elevated MAPK1 expression acts as an unfavorable survival marker, although some lineages such as PDAC and CCRCC show a favorable association.

PDAC, CCRCC, and GBM are the cancer types where MAPK1 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
PDAC	OS	Quartile	All	0.659	0.420	.001	38	view →
CCRCC	DFS	Median	II,III,IV	0.952	0.793	.029	8	view →
GBM	DFS	Tertile	All	0.275	0.510	.030	2	view →

Pink = unfavorable, green = favorable. Showing the 3 strongest of 3 lineages.

MAPK1–PDAC (OS)

Open the PDAC breakdown →